Journal article
Re-Evaluating E-Cadherin and β-Catenin: A Pan-Cancer Proteomic Approach with an Emphasis on Breast Cancer
The American journal of pathology, Vol.188(8), pp.1910-1920
08/2018
DOI: 10.1016/j.ajpath.2018.05.003
PMCID: PMC6119824
PMID: 29879416
Abstract
E-cadherin is conventionally considered to be a good prognostic marker in cancer. The loss of E-cadherin is one of the key hallmarks of epithelial-to-mesenchymal transition, a biological process that promotes cancer cell invasiveness and metastasis. Recent evidence has cast doubt on the importance of epithelial-to-mesenchymal transition in metastasis. The availability of protein-level data in the Cancer Genome Atlas allows for the quantitative analysis of protein and prognosis. The prognostic values of E-cadherin and β-catenin were revisited across 19 cancer types, and high E-cadherin was found to correlate with good prognosis in most cancers. Conversely, higher E-cadherin and β-catenin correlated with shorter survival in invasive breast carcinoma. Stratifying breast cancers by histologic subtype revealed that the poor prognosis of E-cadherin and β-catenin proteins was characteristic of infiltrating ductal, but not lobular, carcinomas. To further corroborate the protein findings and examine cellular localization, immunohistochemistry was used for E-cadherin and β-catenin in 163 breast patient samples from the Iowa cohort. Most previous studies showing that reduced or absent E-cadherin and β-catenin was inversely associated with tumor stages in ductal carcinomas were confirmed. Taken together, these results lead us to question the prognostic values of E-cadherin and β-catenin in ductal carcinomas and indicate a complicated role of E-cadherin and β-catenin in breast cancer progression.
Details
- Title: Subtitle
- Re-Evaluating E-Cadherin and β-Catenin: A Pan-Cancer Proteomic Approach with an Emphasis on Breast Cancer
- Creators
- Nicholas Borcherding - Department of Pathology, College of Medicine, University of Iowa, Iowa City, IowaKimberly Cole - Department of Pathology, College of Medicine, University of Iowa, Iowa City, IowaPaige Kluz - Department of Pathology, College of Medicine, University of Iowa, Iowa City, IowaMichael Jorgensen - Department of Pathology, College of Medicine, University of Iowa, Iowa City, IowaRyan Kolb - Department of Pathology, College of Medicine, University of Iowa, Iowa City, IowaAndrew Bellizzi - Department of Pathology, College of Medicine, University of Iowa, Iowa City, IowaWeizhou Zhang - Department of Pathology, College of Medicine, University of Iowa, Iowa City, Iowa
- Resource Type
- Journal article
- Publication Details
- The American journal of pathology, Vol.188(8), pp.1910-1920
- Publisher
- American Society for Investigative Pathology
- DOI
- 10.1016/j.ajpath.2018.05.003
- PMID
- 29879416
- PMCID
- PMC6119824
- ISSN
- 0002-9440
- eISSN
- 1525-2191
- Grant note
- DOI: 10.13039/100000054, name: National Cancer Institute, award: P30CA086862, R01 CA200673, T32 AI007260, F30 CA206255; DOI: 10.13039/100000002, name: National Institutes of Health, award: P30CA086862, R01 CA200673, T32 AI007260, F30 CA206255
- Language
- English
- Date published
- 08/2018
- Academic Unit
- Dermatology; Pathology; Orthopedics and Rehabilitation; Radiation Oncology
- Record Identifier
- 9984047786802771
Metrics
10 Record Views